Recently, several novel members of the IL-1 family have been identified. The possible
therapeutic utility and the underlying biologic role of these new members remain unclear. In …

Conquering immunosuppression in tumor microenvironments is crucial for effective cancer
immunotherapy. It is well known that interleukin (IL)‐6, a pleiotropic cytokine, is produced in …

Abstract Interleukin (IL)-4 is a crucial cytokine in tumor immunology. In the initial murine
experiments, IL-4 exhibited potent anti-tumor ability. Tumors genetically modified to produce …

IFN-γ knockout mice (GKO) rejected C26 colon carcinoma cells transduced to secrete
interleukin (IL)-12 but do not reject similarly transduced TSA mammary adenocarcinoma …

The increase of interleukin-4 (IL-4) level in tumor environment and the up-regulation of IL-4
receptor (IL-4R) on tumor cells have been long observed. However, their significance for …

Abstract Interleukin 12 (IL-12) has a pivotal role in controlling cell-mediated immunity
through a number of important biological activities, such as secretion of interferon-γ (IFN-γ) …

Abstract Interleukin (IL)‐15, a pleiotropic cytokine, is involved in the development and
maintenance of NK cells and memory CD8+ T cells. We examined the effects of in vivo …

Targeted delivery of IL-12 might turn this cytokine into a safer, more effective cancer
therapeutic. Here we describe a novel immunocytokine, NHS-IL12, consisting of two …

Abstract IL‐15 and IL‐12 display anti‐tumor activity in different models and IFN‐γ has been
reported as a secondary mediator of both IL‐12 and IL‐15 effects. TS/A murine …

IL-2 is a critical T cell growth factor in vitro, but predominantly mediates tolerance in vivo. IL-
2 is mainly produced by CD4+ Th cells, but the role of Th cell-derived IL-2 in vivo is …